Comparing the current results to its competitors, Contineum Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.95 %, recorded in the same quarter.
Contineum Therapeutics Inc , slower than the average decrease reported by the company's competitors of -55.9 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -55.9 %
Contineum Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and both public and private research organizations. Notable competitors include AstraZeneca PLC, Eli Lilly and Company, GSK plc, Johnson & Johnson, and Novartis AG. Its drug candidates, if approved, will compete with established therapies, currently marketed drugs, and other drugs in development across various pharmaceutical approaches and therapy types.
November 18, 2024
Expanding Horizons: Contineum Therapeutics Advances Chronic Pain Treatment with New IND AuthorizationContineum Therapeutics, Inc. a clinical-stage biopharmaceutical company, is making significant strides in the realm of pain management with the recent authorization of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for its therapeutic candidate, PIPE-791. This pivotal move indicates a promising enhancement in the development of novel oral small molecule therapies that are designed to target and alleviate chronic pain, particularly those associated with neurological and inflammatory conditions.Founded with a focused mission to discover and develop innovative trea...
August 1, 2024
The development of novel therapeutic agents has become an imperative focus in the biomedical field, particularly for conditions lacking fully effective treatment options. Recent preclinical data published in the Proceedings of the National Academy of Sciences (PNAS) revealed encouraging findings for PIPE-307, an M1 receptor antagonist currently in development by Contineum Therapeutics, Inc. This article provides an extensive analysis of these findings and their implications for treatment strategies in Relapse-Remitting Multiple Sclerosis (RRMS). Relapse-Remitting Multiple Sclerosis (RRMS) is a chronic, inflammatory, demyelinating condition of the central nervous system characterized by unpredictable episode...
June 25, 2024
Sarah Boyce Appointed to Contineum Therapeutics Board of Directors: Strengthening the Clinical Stage Biopharmaceutical Company s Drug Development StrategiesIn recent news, Contineum Therapeutics, a clinical stage biopharmaceutical company focused on the discovery and development of novel, oral small molecule therapies targeting biological pathways associated with specific clinical impairments, has announced the appointment of Sarah Boyce to their Board of Directors. Boyce currently serves as the President and Chief Executive Officer of Avidity Biosciences, a biotech company listed under Nasdaq as RNA.Contineum Therapeutics aims to combat various neuroscience, inflammation, and immunology (NIandI) indication...
June 24, 2024
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors SAN DIEGO Contineum Therapeutics, Inc. (Nasdaq: CTNM), a forward-thinking clinical stage biopharmaceutical company, has further solidified its executive leadership through the strategic addition of Sarah Boyce to its Board of Directors. Underlying this significant appointment is Contineum Therapeutics’ commitment to revolutionizing the treatment landscape within the realms of neuroscience, inflammation, and immunology (NIandI) through the development of cutting-edge, oral small molecule therapies.Sarah Boyce, who currently serves as the President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), brings...
Publicly Traded Peers of Contineum Therapeutics Inc
Viatris Inc Share Performance
+1.86%
This Quarter
Viatris Inc
Profile
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Sources:
Contineum Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Contineum Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
